Hypoxia inducible factor-1 alpha and prolinhydroxylase 2 polymorphisms in patients with severe sepsis: a prospective observational trial

Annika Höcker, Miriam Rabeling, Alexandra Bick, Linda Cox, Maximilliane Kreuzer, Andrea Engler, Kai Walstein, Hagen S. Bachmann, Karl-Heinz Jöckel, Lewin Eisele, Michael Adamzik, Jürgen Peters and Simon T. Schäfer

Abstract

Background: Hypoxia-inducible-factor-1α (HIF-1α) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic-inflammatory response. Functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs516651 and T/C; SNP rs480902) are associated with altered HIF-1α mRNA nuclear translocation and an altered adaptation to hypoxia. Furthermore, the HIF system is important in surviving inflammatory disorders and sepsis. Thus, we tested the hypotheses, that SNPs in the HIF-1α or PHD2 genes are (1) common in Caucasians, with 2) the HIF-1α genetic variant being associated with an altered HIF-1α mRNA expression; and 3) independent risk factors for 30-day mortality in severe sepsis.

Methods: After ethics approval, 128 septic patients (Caucasian descent) were included prospectively within 24 h after first diagnosing sepsis. Patients characteristics and severity of illness (simplified acute physiology score II), genotypes (Taqman assay), and their influence on leukocyte HIF-1α-mRNA-expression (Real-Time PCR) and 30-day mortality were determined.

Results: Frequencies were 0.8 % for homozygous HIF-1α TT-carriers (CT 17.6 %; CC 81.6 %), 2.5 % for homozygous PHD2 SNP rs516651 TT-allele carriers (CT 17.5 % and CC 80 %), and 9.4 % for homozygous PHD2 SNP rs480902 TT-allele carriers (CT 34.4 % and CC 56.3 %). While HIF-1α T-allele carriers had a borderline decrease in HIF-1α-mRNA-expression (p = 0.06) neither HIF-1α nor PHD2 SNPs were (independent) risk factors for 30-day mortality.

Conclusions: Genetic variants in HIF-1α and PHD2 genes exist in Caucasians but do not appear to alter 30-day mortality in sepsis.

Keywords: Sepsis, Genetic variants, Hypoxia inducible factor, HIF, Polymorphism

* Correspondence: simon.schaefer@uk-essen.de
1Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen and Universität Duisburg-Essen, Hufelandstraße 55, D-45122 Essen, Germany

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hypoxia inducible factor-1α (HIF-1) and HIF-1 degrading prolyl-hydroxylases (PHD) are key regulators of the hypoxic response but are also involved in many cellular actions [1]. Furthermore, we could recently show that leukocyte HIF-1α-mRNA-expression is decreased in severe sepsis and inversely correlated with disease severity [2]. Thus, genetic variants in HIF-1 or HIF-degrading PHD2 could impact on HIF-1α mRNA expression and outcome in septic patients.

Recently, functionally active genetic variants in the HIF-1α (C/T; Single Nucleotide Polymorphism (SNP) rs11549465) and the PHD2 gene (EGLN1; C/T; SNP rs516651 and T/C; SNP rs480902) were identified [3–5] and were associated with increased HIF-1α nuclear translocation and a worse outcome compared to the T-allele genotype in several tumors [6]. However, the HIF-1-pathway plays an important role in adaptation to inflammation, too, as both HIF-1α mRNA and intracellular HIF-1α protein are highly increased following inflammatory stimuli [7, 8]. With persistent inflammation, HIF-1α is suppressed in vitro and even in patients with sepsis, possibly to counter regulating an overwhelming inflammatory response [2, 7, 9]. Furthermore, the HIF-1α T-allele is associated with an adverse outcome in acute injury of the kidney, i.e. an organ with a HIF-mediated oxygen sensor, important in mediating erythropoiesis [1, 10]. In high altitude populations, the PHD2 variant rs480902 CC-genotype is associated with an increased heart rate and higher oxygen saturation under hypoxia, and PHD2 variant rs516651 T-allele carriers are associated with a decreased incidence of acute mountain sickness [5]. Furthermore, PHD deficiency is associated with an altered inflammatory response, i.e., suppressed cytokine expression in mice [11].

Taken together, HIF-1α and PHD2 genetic variations are functionally active but their impact on critical illness has not yet been investigated. Accordingly, we examined potential effects of genetic variants of HIF-1 and HIF degrading PHD2, in severe sepsis. Specifically, we tested the hypotheses, that SNPs in the HIF-1α or PHD2 genes are 1) common in Caucasians with 2) the HIF-1α genetic variant being associated with an altered HIF-1α mRNA expression, and 3) independent risk factors for 30-day mortality in severe sepsis.

Methods
The study was reviewed and approved by the Medical Faculty’s ethic committee (no. 06-3078, University of Duisburg-Essen, Essen, Germany). Adult patients with sepsis admitted to an intensive care unit of the University Hospital Essen, Germany, between 2010 and 2014 were evaluated for inclusion. Patients were considered eligible when they fulfilled the sepsis criteria as defined by Bone et al. [12]. Patients who refused or withdrew study participation, under age persons, and all individuals with non-Caucasian ethnicity were excluded.

Arterial blood samples were taken for blood tests, microbiology cultures, genotyping, and mRNA extraction within the first 24 h after diagnosing sepsis. Furthermore, SAPS II (Simplified Acute Physiology Score II), length of hospitalization, and 30-day mortality were recorded [2, 13].

The characteristics both of septic patients stratified for either genetic variant are displayed in Table 1 (HIF-1α), Table 2 (PHD2 rs516651), and Table 3 (PHD2 rs480902), respectively.

Genotyping
HIF-1α SNP rs11549465 was genotyped using a commercially available Taqman assay (No.: 4351379; Applied Biosystems; Carlsbad, USA) for the context sequence GTTACGTTCCCTCGATCAGTGTTGC[A/C][T]CATTAGAAAGCAGTTCCGCAAGCCC. Vector NTI Advance 11 computer program (Invitrogen, Carlsbad, CA) was used to develop primers for genotyping of PHD2 SNPs. The PHD2 (T/C) SNP (rs480902) was resolved using PCR sense primer 5’-TTTTAAAGGAGTGGGGTA-3’ and anti-sense primer 5’-GGTTGTTGGAATGTAGAAT-3’, while the PHD2 (C/T) SNP (rs516651) was resolved using PCR sense primer 5’-GCAGTTGACCTGCGAGTTTGTGCT-3’ and anti-sense primer 5’-TC TGAAAGGGGTCCAGCAGC-3’. Genotyping was run on a qPCR (Real-Time PCR) System (StepOnePlus™, Applied Biosystem, Carlsbad, USA) at standard conditions (60 °C for 30 min followed by, 95 °C for 10 s, and 15 s at 92 °C and 50 cycles at 60 °C for 1 s).

RNA preparation, qPCR
Whole blood HIF-1α mRNA-expression was analyzed by qPCR following RNA-extraction from the last 62 consecutive patients with severe sepsis included into the study [2, 6]. RNA-extraction was performed on patients’ blood samples using the RNeasy Midi Kit (Qiagen, Hilden, Germany) following manufacturers protocol. One microgram of total RNA was reverse-transcribed to cDNA (complementary deoxyribonucleic acid). As described previously, primers for qPCR were designed using NCBI primer blast (Rockville Pike, MD) and obtained from Invitrogen (Invitrogen AG; Karlsruhe, Germany) [2].

First, qualitative PCR was performed for GAPDH (glyceraldehyde-3-phosphate-dehydrogenase) as a housekeeping gene to test the quality of cDNA synthesis [2, 14]. Second, quantitative PCR was performed to estimate the amount of specific cDNA for HIF-1α [2]. Resulting cDNA bands were visualized using ethidium bromide-stained 1.5 % (w/v) agarose gels [7].
HIF-1α mRNA expression was quantified by qPCR using SYBR® green as fluorescent dye (Eurogentec, Verviers, Belgium) on a StepOnePlus PCR system (Applied Biosystems, Carlsbad, USA). The denaturation steps were performed at 95 °C for 10 min, followed by 40 cycles at 95 °C for 15 s, and at 60 or 61 °C for 1 min, as described previously [2]. Amounts of specific cDNA were finally normalized to GAPDH using the ΔΔct method, and results are depicted as 2ΔΔct values, as described [2].

Statistical analyses
Data are presented as median with quartiles unless indicated otherwise, and in case of categorical variables as numbers and percentages. Data are presented as means ± standard deviation (SD) unless indicated otherwise. The two tailed t-test for independent samples or, in case of violations of the normality assumption (as tested by Kolmogorov-Smirnov and Shapiro-Wilk tests), the Wilcoxon signed rank test was used. Potential deviations from the Hardy-Weinberg equilibrium were ruled out using Court Lab calculator (Court MH; Court-laboratory Hardy-Weinberg calculator; Tufts University; www.tufts.com) for MS Excel 2011 software (Microsoft Deutschland, Unterschleißheim, Germany).

Furthermore, we investigated associations between the patients’ clinicopathologic characteristics and of

| Table 1 Clinicopathologic characteristics of septic patients with genetic variants in the Hypoxia-inducible factor-1α gene (SNP rs11549465) |
|---------------------------------------------------------------|
|                      | HIF 1α  | HIF 1α  | HIF 1α*  | p-value  |
|                      | CC      | CT      | TT       |          |
| n = 102             | n = 22  | n = 1   |          |          |

| Patients’ characteristics |     |
|---------------------------|-----|
| Gender (women/men; %)     | 37/65 (36.3/63.7) 4/18 (18.2/81.8) 1/0 0.103** |
| age (years; median; Q1; Q3) | 56 (48–66) 68 (53–72) 68 0.027* |
| height (cm; median; Q1; Q3) | 172 (165–180) 177 (167–181) 160 0.395* |
| body weight (kg; median; Q1; Q3) | 80 (68–91) 84 (72–92) 80 0.496* |
| BMI (kg m⁻²; median; Q1; Q3) | 26.2 (22.9–30.8) 27.9 (22.7–29.7) 31.3 0.741* |
| Heart rate (min⁻¹; median; Q1; Q3) | 100 (90–125) 107 (85–132) 101 0.870* |
| Mean arterial blood pressure (mmHg; median; Q1; Q3) | 78 (63–90) 70 (63–79) 70 0.200* |
| creatinin serum concentration (mg dl⁻¹; (median; Q1; Q3) | 1.43 (1.0–2.39) 1.71 (0.91–2.58) 2.48 0.749* |
| Dialysis (yes/no; %)     | 67/34 (65.7/33.3) 16/6 (72.7/27.3) 0/1 0.564** |

Primay diagnoses %

|                      |     |
|----------------------|-----|
| Gastrointestinal disease | 25 (29.8) 10 (45.5) 1 |
| Lung disease         | 21 (25) 4 (18.2) |
| Cardiovascular disease | 7 (8.3) 3 (13.6) |
| Hematooncological disease | 6 (7.1) 1 (4.5) |
| Urogenital cancer    | 6 (7.1) 1 (4.5) |
| Intraabdominal pathology, other Cancer, other | 19 (22.6) 3 (13.6) |

Infectious variables

|                      |     |
|----------------------|-----|
| White blood cell count (10⁹ l⁻¹; median; Q1; Q3) | 14.1 (9.8–20.1) 11.2 (6.4–17.0) 18.8 0.220* |
| Procalcitonin concentration (μg l⁻¹; median; Q1; Q3) | 3.0 (1.0–19.2) 3.7 (0.6–9.2) 16.1 0.614* |
| C-reactive protein concentration (g l⁻¹; median; Q1; Q3) | 17.2 (8.8–26.3) 18 (9.7–25.0) 5.6 0.627* |

Disease severity

|                      |     |
|----------------------|-----|
| SAPS II (mean ± SD) | 35 (27–48) 40 (33–50) 41 0.248* |
| Hospital stay (d; mean ± SD) | 23 (13–37) 21 (14–39) 67 0.729* |
| 30-day mortality (%) | 37 (36.3) 10 (45.5) 0 0.502** |
Table 2 Clinicopathologic characteristics of 120 septic patients with genetic variants in the prolyl-hydroxylase 2 gene (SNP rs516651)

| PHD2 CC | PHD2 CT | PHD2 TT | p-value |
|---------|---------|---------|---------|
| n = 96  | n = 21  | n = 3   |         |

| Patients characteristics | PHD2 CC | PHD2 CT | PHD2 TT | p-value |
|--------------------------|---------|---------|---------|---------|
| Gender (women/men; %)    | 38/58   | 5/16    | 1/2     | 0.094** |
| age (years; median; Q1; Q3) | 55 (44–68) | 58 (53–65) | 71 (50–71) | 0.201* |
| height (cm; median; Q1; Q3) | 172 (165–180) | 179 (170–184) | 185 (156–185) | 0.342* |
| body weight (kg; median; Q1; Q3) | 80 (65–90) | 90 (77–110) | 78 (75–78) | 0.205* |
| BMI (kg/m²; median; Q1; Q3) | 26.2 (22.8–30.8) | 28.1 (25.3–34) | 26.3 (22.8–26.3) | 0.434* |
| Heart rate (min⁻¹; median; Q1; Q3) | 100 (90–121) | 113 (94–156) | 90 (70–90) | 0.063* |
| Mean arterial blood pressure (mmHg; median; Q1; Q3) | 75 (63–87) | 73 (61–87) | 76 (63–76) | 0.850* |
| creatinin serum concentration (mg dl⁻¹; median; Q1; Q3) | 1.66 (0.97–2.85) | 1.73 (0.96–2.08) | 1.16 (1.15–1.16) | 0.874* |
| Dialysis (yes/no; %) | 62/34 (64.6/35.4) | 44/70 (60/40) | 100 | 0.619** |

| Primary diagnoses % | PHD2 CC | PHD2 CT | PHD2 TT | p-value |
|---------------------|---------|---------|---------|---------|
| Cardiovascular disease | 5 (6.2) | 2 (11.1) | 1 (33.3) | ** |
| Hematooncological disease | 3 (3.7) | 2 (11.1) | ** |
| Gastrointestinal disease | 33 (40.7) | 4 (22.2) | ** |
| Lung disease | 19 (23.5) | 5 (27.8) | 1 (33.3) | ** |
| Urogenital cancer | 6 (7.4) | 1 (5.6) | ** |
| Intraabdominal pathology, other Cancer, other | 15 (18.4) | 4 (22.2) | 1 (33.3) | ** |

| Infectious variables | PHD2 CC | PHD2 CT | PHD2 TT | p-value |
|----------------------|---------|---------|---------|---------|
| White blood cell count (10⁹ l⁻¹; median; Q1; Q3) | 138 (9.3–20.6) | 155 (8.9–19.1) | 156 (12.2–15.6) | 0.961* |
| Procalcitonin concentration (μg l⁻¹; median; Q1; Q3) | 3.97 (1.2–15.7) | 3.46 (0.31–9.93) | 0.5 (0.23–0.5) | 0.699* |
| C-reactive protein concentration (g l⁻¹; median; Q1; Q3) | 17.7 (9.1–27.3) | 15 (8–21.5) | 18.4 (0.5–18.4) | 0.603* |

| Disease severity | PHD2 CC | PHD2 CT | PHD2 TT | p-value |
|------------------|---------|---------|---------|---------|
| SAPS II (mean ± SD) | 35 (27–44) | 38 (30–50) | 48 (41–48) | 0.107* |
| Hospital stay (d; mean ± SD) | 23 (12–35) | 29 (11–56) | 21 (9–21) | 0.071* |
| 30-day mortality (%) | 33 (34.4) | 8 (38.1) | 2 (66.7) | 0.103** |

Biometric data, primary diagnoses, infectious variables, and disease severity of 120 septic patients. Data were documented at the time of first diagnosing sepsis

*Numbers; p-value based on One-Way-ANOVA;
**Numbers; p-value based on Pearson-Chi-quadrat tests
mean ± standard deviation
median with 25 and 75 % quartiles (median; Q1; Q3);
no statistical test has been applied here
Simplified Acute Physiology Score II

the HIF-1α and PHD2 genotypes with 30-day survival, defined as the interval from time of diagnosis of severe sepsis until day 30 or death, whichever occurred first. Patients alive after the 30-day follow-up were regarded as censored. Kaplan-Meier plots were used to display the overall 30-day survival data in the respective subcohorts followed by log-rank tests for comparison of the different genotypes. Thereafter, we computed hazard ratios and 95 %-CI using multivariate Cox regression models to assess the impact of the respective genotypes (HIF-1α and PHD2 rs516651/rs480902), sex, age, Simplified Acute Physiology Score II, and requirement for dialysis as predictors for the clinical outcome (30-day survival). The proportional hazards assumption was checked for all variables included in the models and no deviation was found (data not shown).

An a priori alpha error p of less than 0.05 was considered statistically significant. In case of more than two groups one-way ANOVA with post hoc Student’s t-test and correction for multiple testing (p = 0.05/n) was used. Interdependence between HIF-1α-mRNA-expression and age was analyzed using Pearson correlation and linear regression analysis.

Statistical analyses were performed using SPSS 21.0 (SPSS Inc., Chicago, IL) and Graph Pad Prism 5 (Graph Pad Software, La Jolla, CA) software. Cox regression models were analysed with SAS Version 9.4 PHREG procedure (SAS Institute, Cary, NC, USA).
Results
In this prospective observational trial we included 128 Caucasian septic patients of which 49 (38.3 %) died within 30 days irrespective of genotype.

Hypoxia inducible factor-1α (C/T rs11549465) polymorphism
Frequencies were 0.8 % for homozygous TT-genotypes, 17.6 % for heterozygous CT-genotypes, and 81.6 % for homozygous CC-genotypes (Table 1). 37 CC-genotypes (36.3 %) and 10 out of 22 CT-genotypes (45.5 %) died within 30 days of study inclusion ($p = 0.502$). For 3 patients, genotyping results were ambiguous, thus patients were excluded from analysis. Kaplan-Meier-graphs (Fig. 1) and multivariate Cox-regression-analyses (Table 4) showed no influence of this genetic variation on 30-day mortality from septic shock. Of note, only a single patient (survivor) carried the homozygous TT-genotype, as shown in Table 1 and Fig. 1. However, this single individual was not included into the statistical analyses.

We then analyzed in 62 samples from consecutive septic patients whether this genetic variant influences HIF-1α-mRNA-expression. Of these patients 17.7 % ($n = 11$) were T-allele carriers of the HIF-1α SNP rs11549465, and 82.3 % were homozygous CC-genotypes (51 patients). HIF-1α-mRNA-expression was decreased by 62 % in T-allele carriers compared to CC-genotypes ($\Delta$ct-values: T-
allele carriers $-8.82 \pm 2.1$ vs. CC-genotypes $-7.45 \pm 2.3$, Fig. 2) but this was of borderline statistical significance ($p = 0.06$), with CT-allele carriers being older (68 years; Q3: 53–72) than individuals with a CC (54 years; Q1-Q3: 48–66) genotype ($p = 0.04$). Of note, HIF-1$\alpha$-mRNA-expression did not correlate with age (Pearson correlation: $r = -0.1$, $p = 0.42$), and HIF1-$\alpha$-mRNA expression did not differ between genotypes even after adjusting for age (data not shown).

Further clinicopathogenic characteristics are displayed in Table 1 and did not differ between groups.

Table 4 Cox regression analyses of septic patients with genetic variants in the Hypoxia-inducible factor-1$\alpha$

| Genotype       | HR (95 %-CI)  | p-value |
|----------------|---------------|---------|
| rs11549465, CT vs. CC | 1.42 (0.68–2.96) | 0.350   |
| rs11549465, TT vs. CC  | NA*           | NA*     |
| Age, per year     | 1.023 (1.001–1.045) | 0.040   |
| Gender, male vs. female | 1.70 (0.87–3.30) | 0.120   |
| Dialysis, yes vs. no  | 2.56 (1.15–5.67) | 0.021   |
| SAPS II, per point  | 1.02 (1.00–1.04)  | 0.059   |

Analysis set $N = 121$. Missing data: rs11549465 genotype ($n = 3$), dialysis ($n = 1$), SAPS II ($n = 3$)

*Only $n = 1$ in the TT group, this patient was censored, thus no HR could be estimated

Prolyl-hydroxylase 2 (C/T; rs516651) polymorphism

Frequencies were 2.5 % for the homozygous TT-genotype, 17.5 % for the heterozygous CT-genotype, and 80 % for the homozygous CC-genotype (Table 2). 33 CC-genotypes (34.4 %), 8 CT- genotypes (38.1 %) and 2 TT-genotypes (66.7 %) died within 30 days of study inclusion ($p = 0.103$). For 8 patients genotyping results were ambiguous, thus patients were excluded from further analyses. Kaplan-Meier-curve analysis (Fig. 3) and multivariate Cox-regression-analysis (Table 5) showed no influence of this genetic variation on 30-day mortality from septic shock. Patients clinicopathogenic characteristics did not differ between groups (Table 2).

Prolyl-hydroxylase 2 (T/C; rs480902) polymorphism

Frequencies were 9.4 % for the homozygous TT-genotype, 34.4 % for the heterozygous CT-genotype, and 56.3 % for homozygous CC-genotype (Table 3). 27 CC-genotypes (37.5 %), 18 CT- genotypes (40.9 %) and 4 TT-genotypes (33.3 %) died within 30 days of study inclusion ($p = 0.876$). Kaplan-Meier-curve analysis (Fig. 4) and multivariate Cox-regression-analysis (Table 6) showed no influence of this genetic variation on 30-day mortality from septic shock. However, the adjusted hazard ratio for mortality was 1.39 (95 %-CI 0.47–4.10) for CC vs. TT genotypes and 1.8 (95 %-CI 0.58–5.59) for CT vs. TT genotypes, suggesting a slight increase in 30-day mortality. Patients’ clinicopathogenic characteristics did not differ between groups (Table 3).

Discussion

In this prospective study we show, that allele frequencies in Caucasian for the functionally active SNPs of the hypoxic-inflammatory response, namely HIF-1$\alpha$ SNP rs11549465, PHD2 rs516651 and rs480902 highly differ from Asian ethnicities. However these SNPs did not...
have a major impact on 30-day mortality in patients with severe sepsis in our sample. Of note, HIF-1α-mRNA-expression showed a trend towards lower expression in HIF-1α T-allele carriers.

HIF-1α SNP frequencies in our Caucasian cohort with sepsis revealed only a single homozygous TT-genotype carrier (0.8 %), whereas 17.6 and 81.6 % carried the heterozygous CT- and homozygous CC-genotypes, respectively. Notably, in people from India the TT-genotype is common with a frequency of 25 %, and 50 % CT-genotypes. T-allele carriers show an association with worse outcomes in metastatic prostate cancer or acute kidney injury [3, 15]. In this prospective study we could not confirm an influence of this SNP on 30-day mortality from severe sepsis. While this might relate to the very low frequency of homozygous TT-genotype carrier in our cohort, 30-day survival also did not differ between HIF-1α CT- and CC-genotypes.

However, HIF-1α mRNA expression showed a trend towards lower expression in T-allele carriers and on average was decreased by 62 %. As we reported previously, decreased HIF-1α mRNA expression inversely correlates with sepsis severity, i.e., with greater HIF-1α mRNA expression and intracellular HIF-1α protein suppression in patients with higher Simplified Acute Physiology Score II (SAPS II) [2]. As a high SAPS II is associated with increased mortality, one might expect increased mortality in HIF-1α T-allele carriers as well, however one might emphasize that sepsis itself contributes stronger to alterations in HIF-1α mRNA expression.

Table 5 Cox regression analyses of septic patients with genetic variants in the prolyl-hydroxylase 2 gene (rs516651)

|                    | HR (95 % CI)  | p-value |
|--------------------|---------------|---------|
| rs516651, CC vs. TT| 1.15 (0.50–2.66) | 0.730   |
| rs516651, CT vs. TT| 1.52 (0.35–6.65) | 0.570   |
| Age, per year      | 1.017 (0.99–1.040) | 0.120   |
| Gender, male vs. female | 1.71 (0.87–3.36) | 0.120   |
| Dialysis, yes vs. no | 1.99 (0.90–4.38) | 0.087   |
| SAPS II, per point | 1.015 (0.99–1.04) | 0.180   |

Analysis set: N = 116. Missing data: rs516651 genotype (n = 8), dialysis (n = 1), SAPS II (n = 3)

Table 6 Cox regression analyses of septic patients with genetic variants in the prolyl-hydroxylase 2 gene (rs480902)

|                    | HR (95 % CI)  | p-value |
|--------------------|---------------|---------|
| rs480902, CT vs. TT| 1.39 (0.47–4.10) | 0.550   |
| rs480902, CC vs. TT| 1.80 (0.58–5.59) | 0.310   |
| Age, per year      | 1.025 (1.003–1.048) | 0.025   |
| Gender, male vs. female | 1.62 (0.85–3.10) | 0.140   |
| Dialysis, yes vs. no | 2.06 (0.98–4.30) | 0.056   |
| SAPS II, per point | 1.018 (0.99–1.038) | 0.074   |

Analysis set: N = 124. Missing data: dialysis (n = 1), SAPS II (n = 3)
than this genetic variant does [13]. However, sepsis is a heterogeneous disease with multiple factors contributing to the patients’ mortality. Even, in our previous study HIF-1α mRNA-expression correlated with disease severity but not with outcome [2].

In a next step we analyzed genetic variants in the HIF-1α degrading PHD2 gene, as these SNPs are associated with an increased oxygen saturation and heart rate in response to hypoxia and thus improved adaptation [5]. Furthermore, a PHD2 knockout in mice inhibits TNFα and ICAM-1 expression with reduced cell apoptosis and macrophage infiltration [11].

Therefore, we determined the genotype frequencies of PHD2 SNP rs516651 carriers in our Caucasian cohort, with homozygous TT-genotypes found in 2.5 % of septic patients and heterozygous CT-genotypes in 17.5 %. Thus, we show that this SNP is present in Caucasians whereas in Tibetan high altitude residents, T-allele carriers do not exist [5].

In a next step we analyzed genetic variants in the HIF-1α degrading PHD2 gene, as these SNPs are associated with an increased oxygen saturation and heart rate in response to hypoxia and thus improved adaptation [5]. Furthermore, a PHD2 knockout in mice inhibits TNFα and ICAM-1 expression with reduced cell apoptosis and macrophage infiltration [11].

The PHD2 SNP rs480902, was common in Caucasians as well, however frequencies for homozygous TT-genotypes (9.4 %) and CT-genotypes (34.4 %), were lower when compared to Tibetan high altitude residents with frequencies of T-allele carriers of up to 75 % [5].

However, the PHD2 SNP rs480902 genotype did not impact on 30-day mortality. PHD2 is a key-regulator of HIF-1α in erythropoietin producing cells and, therefore, crucial for regulation of erythropoietin secretion [16]. In mice, PHD2 deficiency leads to pronounced erythrocytosis due to a suppressed HIF-1α degradation and hence activation of the erythropoietin pathway, [16] as well as to increased angiogenesis [17]. Whereas regulation of erythrocytosis usually represents moncausal mid to long-term changes, severe sepsis is an acute life-threatening disorder depending on many issues. This might explain why PHD2 genetic variants did not impact on survival in our cohort.

Our study has limitations: First, given the low genotype frequencies for the homozygous HIF-1α and PHD2 rs516651 TT-genotype, 128 septic patients still need to be considered a small sample, reducing the explanatory power of our analysis. Thus, reanalyzing the influence of HIF-1α and PHD2 SNPs in a larger cohort of septic patients is warranted. Furthermore, in this study we did not analyze the impact of either genetic variant on the patients phenotype i.e. regarding immune cell function or blood coagulation. This is of particular interest as other genetic variants, i.e. the NFKB1 promoter polymorphism -94ins/deATTG, turned out to be an independent predictor for 30-day mortality from septic shock, in a similar patients cohort of 143 patients [18].

In detail, the Deletion-allele was associated with altered blood coagulation and hyperinflammation [18]. Second, due to ethics issues and restrictions we only could analyze HIF-1α mRNA expression from the last 62 consecutive patients only at one time point. Analyzing HIF-1α mRNA expression in the course of sepsis depending on genetic variants might help to understand the regulation of the hypoxic-inflammatory pathway in the critically ill. More important, leukocyte HIF-1α mRNA expression was suppressed in T-allele carriers when compared to the CC-genotype, but this failed to reach statistical significance (p = 0.06). However, such variations in HIF-1α mRNA expression in T-allele carriers, are in accordance with the large variation of leukocyte HIF-1α expression in septic patients, [2] as well as a worse outcome of T-allele carriers with metastatic prostate cancer [6]. Third, septic patients are a very heterogeneous cohort due to various entities of sepsis or comorbidities. Thus, it might be favorable to analyze these polymorphisms in a cohort with a more homogenous sepsis entity, e.g., in patients with acute respiratory distress syndrome.

Conclusions

In conclusion, genetic variants in HIF-1α and PHD2 genes exist in Caucasians. However, homozygous TT-genotypes are infrequent and range from 0.8 % for HIF-1α SNP rs516651 to 9.4 % for PHD2 SNP rs480902. Furthermore, even in our rather small sample, T-allele carriers of the HIF-1α SNP show a trend towards further suppressed HIF-1α mRNA expression compared to CC genotypes. However, neither of the analyzed genetic variants of HIF-1α and PHD2 genes turned out to be independent risk factors for 30-day mortality of severe sepsis. Reanalyzing the influence of these genetic variants in a larger and more homogenous patients cohort i.e. patients with Acute respiratory distress syndrome (ARDS) is warranted to confirm the findings of our study.

Abbreviations

HIF-1α, hypoxia-inducible-factor-1α; PHD, HIF-1α degrading prolyl-hydroxylases; SAPSI, simplified acute physiology score II; SNP, single nucleotide polymorphism

Acknowledgments

We want to thank Ursula Brecklinghaus, MTA and Baerbel Hermann, MTA for the great support regarding genotyping and qPCR.
Funding
The study was funded by departmental resources as well as a research grant given to PD Dr Schaefer from the medical faculty of the university hospital Essen (IFORES research grant no: D/1017-40240). However, the authors declare that they do not have any competing interests, i.e. the research grant given from the Medical Faculty of the University Duisburg-Essen to PD Dr. Simon Schäfer did not affect study design, data collection, analysis, interpretation of data, writing of the manuscript or the decision to submit the manuscript for publication.

Availability of data and materials
All relevant data and materials are presented in the manuscript.

Authors’ contributions
HA, SST, and PJ conceived and conducted the study, HA, RM, EA, BHS, and WK designed primers, and established and performed the genotyping. BA, KM, and CL performed mRNA extraction and qPCR. HA, BA, and STS analyzed the data. EL and JRH provided statistical analyses. SST and PJ provided experimental experience and revised the manuscript. All authors read and approved the final manuscript.

Authors’ information
PD Dr S. Schaefer’s current working address is Klinik für Anästhesiologie, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Marchioninistraße 15, 81377 München.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Written informed consent was obtained from the patient or the patients guardian. Patients who refused or withdrew study participation, underage persons, and all individuals with non-Caucasian ethnicity were excluded.

Ethics approval and consent to participate
The study was reviewed and approved by the Medical Faculty’s ethics committee (no. 06–3078, University of Duisburg-Essen, Essen, Germany).

Author details
1Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen and Universität Duisburg-Essen, Hufelandstraße 55, D-45122 Essen, Germany. 2Institut für Pharmakogenetik, Universitätsklinikum Essen and Universität Duisburg-Essen, Essen, Germany. 3Institut für Medizinische Informatik, Biometrie und Epidemiologie, Universitätsklinikum Essen and Universität Duisburg-Essen, Essen, Germany.

Received: 5 December 2015 Accepted: 15 July 2016
Published online: 11 August 2016

References
1. Schwartz RS, Eltzschig HK, Carmeliet P. Hypoxia and Inflammation. N Engl J Med. 2011;364:656–65.
2. Schafer ST, Frede S, Winning S, Bick A, Roshanar R, Fandrey J, Peters J, Adamzik M. Hypoxia-inducible factor and target gene expression are decreased in patients with sepsis: prospective observational clinical and cellular studies. Anesthesiology. 2013;118:426–36.
3. Fraga A, Ribeiro R, Principe P, Lobato C, Pina F, Mauricio J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R. The HIF-1α functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. Eur J Cancer. 2014;50:359–65.
4. Pichu S, Sathiyamoorthy J, Krishnamoorthy U, Umapathy D, Viswanathan V. Impact of the hypoxia inducible factor-1α (HIF-1α) pro582ser polymorphism and its gene expression on diabetic foot ulcers. Diabetes Res Clin Pract. 2015;109:533–40.
5. Buroker NE, Ning X-H, Zhou Z-N, Li K, Cen W-J, Wu Y-F, Zhu W-Z, Scott CR, Chen SH. EPAS1 and EGLN1 associations with high altitude sickness in Han and Tibetan Chinese at the Qinghai–Tibetan Plateau. Blood Cell Mol Dis. 2012;49:67–73.
6. Lessi F, Mazzanti CM, Tomei S, Di Cristofano C, Minervini A, Menicagli M, Apollo A, Masieri L, Collecchi P, Minervini R, Carini M, Bevilacqua G, VHL and HIF-1α gene variations and prognosis in early-stage clear cell renal cell carcinoma. Med Oncol. 2014;31:840.
7. Frede S, Stockmann C, Winning S, Freitag P, Fandrey J. Hypoxia-Inducible Factor (HIF) 1 Accumulation and HIF Target Gene Expression Are Impaired after Induction of Endotxin Tolerance. J Immunol. 2009;182:6470–6.
8. Frede S, Berchner-Pfannschmidt U, Fandrey J. Regulation of Hypoxia-Inducible Factors During Inflammation. In Methods in Enzymology. Volume 435. Amsterdam: Elsevier; 2007:403–419. [Methods in Enzymology] http://dx.doi.org/10.1016/S0076-6879(07)53021-0.
9. Frede S, Stockmann C, Freitag P, Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB. Biochem J. 2006;396:517–27.
10. Varma S, Cohen HJ. Co-transactivation of the 3' erythropoietin hypoxia inducible enhancer by the HIF-1 protein. Blood Cell Mol Dis. 1997;23:169–76.
11. Zeng H, Chen J-X. Conditional Knockout of Prolyl Hydroxylase Domain Protein 2 Ateenuates High Fat-Diet-Induced Cardiac Dysfunction in Mice. PLoS ONE. 2014;9:e15974.
12. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaut WA, Schein RM, Sibbald WJ, ACCP/SCCM Consensus Conference Committee. Definitions for Sepsis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 136:2009.
13. Aegerters P, Boumendil A, Rebi L, Mirvelli E, Denvaux B, Guidet B. SAPS II revisited. Intensive Care Med. 2005;31:416–23.
14. Winer J, Jung CK, Shackell I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:401–9.
15. Kolyada AF, Tighiouart H, Perianayagam MC, Liangos O, Madias NE, Jaber BL. A genetic variant of hypoxia-inducible factor-1α is associated with adverse outcomes in acute kidney injury. Kidney Int. 2009;75:1222–9.
16. Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, McMullin MF, Lee FS. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A. 2006;103:654–9.
17. Takeda K, Agula HL, Parikh NS, Li X, Lamothe K, Duan LJ, Takada H, Lee FS, Fong GH. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 2008;112:3229–35.
18. Adamzik M, Schäfer S, Frey UH, Becker A, Kreuzer M, Winning S, Frede S, Steinmann J, Fandrey J, Zacharowski K, Siffert W, Peters J, Hartmann M. The NFκB1 promoter polymorphism (–94ins/delATTG) alters nuclear translocation of NFκB1 in monocytes after lipopolysaccharide stimulation and is associated with increased mortality in sepsis. Anesthesiology. 2013;118:123–33.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit